Search

Your search keyword '"Memmos, D"' showing total 168 results
Start Over Author "Memmos, D" Publication Year Range Last 50 years
168 results on '"Memmos, D"'

7. Risk of Hospitalization Associated With Body Mass Index and Weight Changes Among Prevalent Haemodialysis Patients

Author

Carrero, J, Rodríguez-Cabezas, I, Qureshi, A, Floege, J, Ketteler, M, London, G, Locatelli, F, Memmos, D, Goldsmith, D, Ferreira, A, Nagy, J, Teplan, V, Martínez-Salgado, C, Fernández-Martín, J, Zoccali, C, Cannata-Andia, J, COSMOS Group, and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Subjects
Male, medicine.medical_specialty, 030232 urology & nephrology, Weight changes, Overweight, lcsh:RC870-923, Risk Assessment, Body Mass Index, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, Thinness, Weight loss, Hospitalization / statistics & numerical data, Renal Dialysis, Internal medicine, Chronic kidney disease, medicine, Humans, Hospitalization risk, 030212 general & internal medicine, Poisson regression, Obesity, Prospective Studies, Nutritional markers, Obesity / epidemiology, Aged, business.industry, Incidence (epidemiology), Weight change, Body Weight, nutritional and metabolic diseases, HCC NEF, Middle Aged, lcsh:Diseases of the genitourinary system. Urology, Hospitalization, Nephrology, symbols, Female, Underweight, medicine.symptom, business, Body mass index, Weight gain, Thinness / epidemiology
Abstract

COSMOS is sponsored by the Bone and Mineral Research Unit (Hospital Universitario Central de Asturias), SAFIM (Sociedad Asturiana Fomento Investigaciones Óseas), the European Renal Association-European Dialysis and Transplant Association, the National Program of I+D+I 2008–2011 and Instituto de Salud Carlos III (ISCIII), the ISCIII Retic REDinREN (RD06/0016/1013 and RD12/0021/1023), the ISCIII (ICI14/00107 and PI17/00384), Fondo Europeo de Desarrollo Regional (FEDER), Plan Estatal de I+D+I 2013–2016, Plan de Ciencia, Tecnología e Innovación 2013–2017 del Principado de Asturias (GRUPIN14-028) and Fundación Renal Ínigo Álvarez de Toledo (FRIAT), Carrero, J.J., Cabezas-Rodríguez, I., Qureshi, A.R., Floege, J., Ketteler, M., London, G., Locatelli, F., Memmos, D., Goldsmith, D., Ferreira, A., Nagy, J., Teplan, V., Martínez-Salgado, C., Fernández-Martín, J.L., Zoccali, C., Cannata-Andia, J.B., on behalf of the COSMOS group

Published
2018
Full Text
View/download PDF

8. Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial

Author

Macdougall, I. C., Bock, A. H., Carrera, F., Eckardt, K. -U., Gaillard, C., Van Wyck, D., Meier, Y., Larroque, S., Perrin, A., Roger, S. D., Gilles, Auguste, Faull, R., Toussaint, N. D., Mcmahon, L., Suranyi, M., Mudge, D., Hutchison, B., Irish, A., Kerr, P., Kulkarni, H., Elder, G., Jardine, M., Lhotta, K., Mayer, G., Vanholder, R., Maes, B. D., Evenepoel, P., Debelle, F., Jadoul, M., Dratwa, M., Macel, I., Dunaj, M., Kvapil, M., Bucek, P., Rehorova, J., Hruby, A., Honova, V., Malanova, L., Lucak, M., Lecian, D., Jirovec, M., Vlasak, J., Rychlik, I., Surel, S., Kamper, A. -L., Ostergaard, O., Steffensen, G. K., Chenine, L., Choukroun, G., Zaoui, P., Wanner, C., Backs, W., Kraatz, U., Dellanna, F., Busch, K., Marsen, T., Seeger, W., Woitas, R., Obermueller, N., Haak, T., Lueders, S., Pistrosch, F., Mueller, E., Mertens, P. R., Sutermer, W., Grebe, S. -O., Hafezi-Rachti, S., Roeser, S., Tsakiris, D., Memmos, D., Vlachakos, D., Vargemezis, V., Stefanidis, I., Syrganis, C., Alivanis, P., Papadakis, I., Papagalanis, N., Andrikos, A., Goumenos, D., Siamopoulos, K., Gouva, C., Papadakis, G., Boletis, I., Tsimnadi-Spanoudaki, M., Stamatiades, D., Stamatelou, K., Moutafis, S., Locatelli, Federica, Santoro, A., Quarello, F., Remuzzi, G., Coppola, S., Mortellaro, R. F., Icardi, A., Colussi, G., Grotta, F. D., Lombardi, L., Gallieni, M., Villa, G., Grandaliano, Giuseppe, Huisman, S., Barendregt, J., Gregoor, P. J. H., Oien, C., Rutkowski, B., Malecki, R., Nowicki, M., Rutkowski, P., Marczewski, K., Mysliwiec, M., Sydor, A., Rysz, J., Rydzewski, A., Klinger, M., Wnuk, R., Kozminski, P., Nocon, A., Ciechanowski, K., Correia, P., Neves, F., Barata, J., Mircescu, G., Voiculescu, M., Gluhovschi, G., Mota, E., De Francisco, A. L. M., Torre, A., Herreros, A., Luno, J., Gruss, E., Martins, J., Valles, M., Pascual, J., Barany, P., Ambuehl, P. M., Erturk, S., Arici, M., Paydas, S., Soypacaci, Z., Camsari, T., Ustundag, S., Thomas, M. E., D'Souza, R. J., Taylor, J. E., Pritchard, N. R., Jeffery, R., Riley, S. G., Bhatnagar, D., Bhandari, S., Reaich, D., Stevens, P. E., El Kossi, M., Roe, S., Camilleri, B., Ahmed, A., Khwaja, A., Thompson, B., Banerjee, D., Nicholas, J., Hutchison, A., Borrows, R., and Groningen Kidney Center (GKC)

Subjects
0301 basic medicine, Male, 030232 urology & nephrology, Administration, Oral, Gastroenterology, oral, 0302 clinical medicine, DIALYSIS, nondialysis, Settore MED/14 - NEFROLOGIA, Erythropoiesis, SUCROSE, Aged, 80 and over, education.field_of_study, biology, Anemia, General Medicine, Iron deficiency, RANDOMIZED CONTROLLED-TRIAL, Middle Aged, Nephrology, Female, INTRAVENOUS FERRIC CARBOXYMALTOSE, Research Article, Adult, medicine.medical_specialty, Iron, Population, supplement, 03 medical and health sciences, Multicenter trial, Internal medicine, medicine, DEFICIENCY ANEMIA, Humans, Renal Insufficiency, Chronic, education, Aged, Transferrin saturation, business.industry, ferritin, hemoglobin, medicine.disease, Ferritin, 030104 developmental biology, biology.protein, Hemoglobin, business, Kidney disease
Abstract

Aims: To evaluate erythropoietic response rates to oral iron over time in iron-deficient anemic patients with nondialysis-dependent chronic kidney disease (ND-CKD). Materials and methods: FIND-CKD was a 1-year, randomized, multicenter trial of iron therapy in patients with ND-CKD, anemia, and iron deficiency, without erythropoiesis-stimulating agent (ESA) therapy. Patients with active infection or C-reactive protein > 20 mg/L were excluded. In this post-hoc analysis, response was defined as >= 1 g/dL increase in hemoglobin (Hb) from baseline, before initiation of alternative anemia therapy (i.e., ESA, transfusion, or intravenous iron). Results: 308 patients received oral iron (200 mg elemental iron/day). Mean (SD) Hb at baseline was 10.4 (0.7) g/dL. At week 4, Hb data were available from 292 patients without alternative anemia therapy: 63/292 (21.6%) showed a response. Among the 229 nonresponders at week 4, 48.8% showed a cumulative response on >= 1 occasion by week 52 (11.1%, 19.9%, 25.9%, and 28.7% had a response at weeks 8, 12, 24, and 52, respectively), and 27.9% had received alternative iron therapy by week 52. Baseline levels of Hb, ferritin, and transferrin saturation were lower in responders than in nonresponders. Neither concomitant medication nor adherence (as assessed by medication count) was substantially different between early responders and nonresponders. Conclusion: Four weeks after starting oral iron therapy, only 21.6% of anemic patients with ND-CKD and iron deficiency showed an Hb increase of at least 1 g/dL. Among early nonresponders

Published
2017

14. Effect of membrane permeability on survival of hemodialysis patients

Author

Locatelli F, Martin Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R, La Milia V, Pozzi M, Di Filippo S, La Greca G, Brendolan A, Crepaldi C, Maschio G, Loschiavo C, Barbieri C, Milanesi F, Redaelli B, Stella A, Viganò MR, Stellato T, Villa G, Segagli S, Montagna G, Quarello F, Vallero A, Forneris G, Borghi M, Tagliaferri M, Palmerio G, Imbasciati E, Farina M, Bucci R, Stallone C, Aucella F, Bellazzi C, De Vincenti A, Giannattasio M, Detomaso F, Malberti F, Pecchini P, Fabris A, Zanella M, Feriani M, Genchi R, Fraticelli M, D'Amico M, Bernardi LE, Palumbo R, De Cicco C, Pietrzak I, Drobnik M, Weyde W, Krajewska M, Penar J, Aljama P, Martín Malo A, Berdud I, Alvarez de Lara MA, Navas A, Martín García J, Chacón JC, Junco E, López Gómez JM, Villaverde M, Bustamante J, Martín García D, Sánchez L, Montenegro J, Ocharan J, Barril G, Besada E, Pastor JM, Gallar P, Almaraz M, Alcalá M, Silgado G, Gruss E, Portolés JM, Delgado R, Bittar H, Nony A, Chanard J, Randoux C, Maheut H, Dimitrov Y, Bouiller M, Simon P, Kim SA, Cremault A, Ryckelynck JP, Levaltier B, Jonon B, Saidani F, Maurice F, Kessler M, Hachicha M, Reach I, Bataille P, Nour D, Paiva A, Cruz J, Carvalho D, Buinho F, Santos JP, Sotto K, Sousa S, da Cruz L, Henriques C, Santos J, Vinhas J, Assunçao J, Memmos D, Belechri AM, Giamalis P, Dhondt A, Veys N, Van Biesen W, Verbeelen D, Krzesinski JM, Tielemans C, Lins R, Larsson K, Kurkus J, Weiss L, Welander G, Seidel S, Lotz C, Gruber H, Weinreich T, Rawer P, Bommer J, Hoenich NA, Leunissen K.L., STEFONI, SERGIO, CIANCIOLO, GIUSEPPE, BARALDI, OLGA, Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R, La Milia V, Pozzi M, Di Filippo S, La Greca G, Brendolan A, Crepaldi C, Stefoni S, Cianciolo G, Baraldi O, Maschio G, Loschiavo C, Barbieri C, Milanesi F, Redaelli B, Stella A, Viganò MR, Stellato T, Villa G, Segagli S, Montagna G, Quarello F, Vallero A, Forneris G, Borghi M, Tagliaferri M, Palmerio G, Imbasciati E, Farina M, Bucci R, Stallone C, Aucella F, Bellazzi C, De Vincenti A, Giannattasio M, Detomaso F, Malberti F, Pecchini P, Fabris A, Zanella M, Feriani M, Genchi R, Fraticelli M, D'Amico M, Bernardi LE, Palumbo R, De Cicco C, Pietrzak I, Drobnik M, Weyde W, Krajewska M, Penar J, Aljama P, Martín Malo A, Berdud I, Alvarez de Lara MA, Navas A, Martín García J, Chacón JC, Junco E, López Gómez JM, Villaverde M, Bustamante J, Martín García D, Sánchez L, Montenegro J, Ocharan J, Barril G, Besada E, Pastor JM, Gallar P, Almaraz M, Alcalá M, Silgado G, Gruss E, Portolés JM, Delgado R, Bittar H, Nony A, Chanard J, Randoux C, Maheut H, Dimitrov Y, Bouiller M, Simon P, Kim SA, Cremault A, Ryckelynck JP, Levaltier B, Jonon B, Saidani F, Maurice F, Kessler M, Hachicha M, Reach I, Bataille P, Nour D, Paiva A, Cruz J, Carvalho D, Buinho F, Santos JP, Sotto K, Sousa S, da Cruz L, Henriques C, Santos J, Vinhas J, Assunçao J, Memmos D, Belechri AM, Giamalis P, Dhondt A, Veys N, Van Biesen W, Verbeelen D, Krzesinski JM, Tielemans C, Lins R, Larsson K, Kurkus J, Weiss L, Welander G, Seidel S, Lotz C, Gruber H, Weinreich T, Rawer P, Bommer J, Hoenich NA, and Leunissen KL.

Subjects
medicine.medical_specialty, HEMODIALYSIS, HEMODIALYSIS PATIENT SURVIVAL, Membrane permeability, business.industry, medicine.medical_treatment, HIGH-FLUX HEMODIALYSIS MEMBRANES, Hazard ratio, LOW-FLUX HEMODIALYSIS MEMBRANES, General Medicine, ALBUMIN, Gastroenterology, Confidence interval, law.invention, Randomized controlled trial, Nephrology, law, Internal medicine, Clinical endpoint, Medicine, Hemodialysis, business, Survival rate, Dialysis
Abstract

The effect of high-flux hemodialysis membranes on patient survival has not been unequivocally determined. In this prospective, randomized clinical trial, we enrolled 738 incident hemodialysis patients, stratified them by serum albumin < or = 4 and >4 g/dl, and assigned them to either low-flux or high-flux membranes. We followed patients for 3 to 7.5 yr. Kaplan-Meier survival analysis showed no significant difference between high-flux and low-flux membranes, and a Cox proportional hazards model concurred. Patients with serum albumin < or = 4 g/dl had significantly higher survival rates in the high-flux group compared with the low-flux group (P = 0.032). In addition, a secondary analysis revealed that high-flux membranes may significantly improve survival of patients with diabetes. Among those with serum albumin < or = 4 g/dl, slightly different effects among patients with and without diabetes suggested a potential interaction between diabetes status and low serum albumin in the reduction of risk conferred by high-flux membranes. In summary, we did not detect a significant survival benefit with either high-flux or low-flux membranes in the population overall, but the use of high-flux membranes conferred a significant survival benefit among patients with serum albumin < or = 4 g/dl. The apparent survival benefit among patients who have diabetes and are treated with high-flux membranes requires confirmation given the post hoc nature of our analysis.

Published
2009

17. Geographical variability of patient characteristics and treatment patterns affect outcomes for incident hemodialysis patients

Author

Martin-Malo, A., Papadimitriou, M., Cruz, J., Bustamante, J., Verbeelen, D., Nony, A., Vanholder, R., Jacobson, S. H., Montenegro, J., Hannedouche, T., Wizemann, V., Locatelli, F., La Milia, V., Pozzi, M., Di Filippo, S., La Greca, G., Ronco, C., Brendolan, A., Crepaldi, C., Stefoni, S., Ciancialo, G., Baraldi, O., Maschio, G., Loschiavo, C., Barbieri, C., Milanesi, F., Redaelli, B., Stella, A., Vigano, M. R., Stellato, T., Villa, G., Segagli, S., Montagna, G., Quarello, F., Vallero, A., Forneris, G., Borghi, M., Tagliaferri, M., Palmerio, G., Imbasciati, E., Farina, M., Bucci, R., Stallone, C., Aucella, F., Bellazzi, C., De Vincenti, A., Giannattasio, M., Detomaso, F., Malberti, F., Pecchini, P., Fabris, A., Zanella, M., Feriani, M., Genchi, R., Fraticelli, M., D'Amico, M., Bernardi, L. E., Palumbo, R., De Cicco, C., Czekalski, S., Pietrzak, I., Drobnik, M., Weyde, W., Krajewska, M., Penar, J., Aljama, P., Martin Malo, A., Berdud, I., Alvarez De Lara, M. A., Navas, A., Martin Garcia, J., Chacon, J. C., Junco, E., Lopez Gomez, J. M., Villaverde, M., Martin Garcia, D., Sanchez, L., Ocharan, J., Barril, G., Besada, E., Pastor, J. M., Gallar, P., Almaraz, M., Alcala, M., Silgado, G., Gruss, E., Portoles, J. M., Delgado, R., Bittar, H., Chanard, J., Randoux, C., Maheut, H., Dimitrov, Y., Bouiller, M., Simon, P., Ang, K. S., Cremault, A., Ryckelynck, J. -P., Levaltier, B., Jonon, B., Saidani, F., Maurice, F., Kessler, M., Hachicha, M., Reach, I., Bataille, P., Nour, D., Loureiro, A., Paiva, A., Carvalho, D., Buinho, F., Santos, J. P., Sotto, K., Sousa, S., Da Cruz, L., Henriques, C., Santos, J., Vinhas, J., Assuncao, J., Memmos, D., Belechri, A. M., Giamalis, P., Dhondt, A., Veys, N., Van Biesen, W., Krzesinski, J. -M., Tielemans, C., Lins, R., Larsson, K., Kurkus, J., Weiss, L., Welander, G., Seidel, S., Lotz, C., Gruber, H., Weinreich, T., Rawer, P., Martin-Malo, Alejandro, Papadimitriou, Menelao, Cruz, Joao, Bustamante, Jesu, Verbeelen, Dierik, Nony, Alain, Vanholder, Raymond, Jacobson, Stefan H., Montenegro, Jesu, Hannedouche, Thierry, Wizemann, Volker, Locatelli, Francesco, Membrane Permeability Outcome (MPO) Study Group [.., Baraldi, Olga, and ].

Subjects
Male, Pediatrics, Epidemiology, Prevalence, Comorbidity, Kaplan-Meier Estimate, Comorbidities, Renal Dialysi, Cardiovascular Disease, Medicine, education.field_of_study, Europe, Hemodialysis, Mortality, Practice patterns, Hazard ratio, Diabetes Mellitu, Vascular Access Device, Middle Aged, Treatment Outcome, Cardiovascular Diseases, Nephrology, Female, Comorbiditie, Hemodialysi, Vascular Access Devices, Human, medicine.medical_specialty, Membrane permeability, Population, Permeability, Practice pattern, Renal Dialysis, Confidence Intervals, Diabetes Mellitus, Humans, Renal Insufficiency, Chronic, education, Survival analysis, Serum Albumin, Proportional Hazards Models, Aged, Analysis of Variance, business.industry, Proportional hazards model, Membranes, Artificial, Cholesterol, LDL, medicine.disease, Proportional Hazards Model, Calcium, business, Confidence Interval, Demography, Kidney disease
Abstract

Background: Geographical differences in disease prevalence and mortality have been described in the general population and in chronic kidney disease patients in Europe. In this secondary analysis of the Membrane Permeability Outcome (MPO) study, we addressed differences in patient and treatment patterns, and whether these affect patient outcomes. Methods: Participating countries were grouped according to geographical location; thus study centers in France, Greece, Italy, Portugal and Spain were allocated to southern Europe (n=499), and those in all other countries (Belgium, Germany, Poland and Sweden) to northern Europe (n=148). Descriptive analysis of patient and treatment patterns at study start, as well as survival analysis, was performed. Results: In patients from the northern European countries, a higher prevalence of diabetes mellitus and of cardiovascular disease was observed than in those from southern Europe (diabetes 35.1% vs. 21.0%, p=0.0007; cardiovascular disease 40.5% vs. 22.8%, p

Published
2013

18. FP473THE USE OF HIGH-FLUX MEMBRANES IS NOT ASSOCIATED WITH IMPROVED SURVIVAL OF PATIENTS ON HEMODIALYSIS

Author

Sanchez, E, primary, Fernández-Martín, J L, additional, Floege, J, additional, Ketteler, M, additional, London, G, additional, Locatelli, F, additional, Gorriz, J L, additional, Rutkowski, B, additional, Memmos, D, additional, Covic, A, additional, Nagy, J, additional, Goldsmith, D, additional, Benedik, M, additional, and Cannata-Andía, J B, additional

Published
2015
Full Text
View/download PDF

19. Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS)

Author

Cannata-Andía, J. B., Fernández-Martín, J. L., Zoccali, C., London, G. M., Locastelli, F., Ketteler, M., Ferreira, A., Covic, A., Floege, J., Górriz, J. L., Rutkowski, B., Memmos, D. E., Verbeelen, D., Tielemans, C., Teplan, V., Bos, W. J., Judit Nagy, Kramar, R., Goldsmith, D. J. A., Martin, P. -Y, Wüthrich, R. P., Pavlovic, D., Benedik, M., University of Zurich, and Cannata-Andía, J B

Subjects
ddc:616, Research Design, 2727 Nephrology, Kidney Diseases/complications, 610 Medicine & health, Observation, Hyperparathyroidism, Secondary/*diagnosis/etiology/metabolism, Renal Dialysis/adverse effects, Bone Density, Renal Dialysis, Humans, Multicenter Studies as Topic, 10035 Clinic for Nephrology, Hyperparathyroidism, Secondary, Kidney Diseases, Biological Markers/analysis, Biomarkers, Multicenter Studies as Topic/methods
Abstract

STUDY AIMS: To survey bone mineral disturbances in the hemodialysis (HD) population in Europe and current clinical practice in Europe for the prevention, diagnosis and treatment of secondary hyperparathyroidism (SHPT) in HD patients. PRIMARY OBJECTIVES: First, to estimate the prevalence of Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline achievement in a representative sample of European hemodialysis subjects. As part of this objective, we will investigate the prevalence of achievement by type of dialysis, type of center and time on dialysis (less than or greater than 1 year). Among new dialysis subjects (less than 1 year), we will evaluate prevalence of K/DOQI target achievement until the end of the study. The study will run for 3 years. Second, to estimate the association of bone mineral markers (parathyroid hormone [PTH], calcium [Ca], serum phosphorus [P] and calcium phosphate product [CaxP]) classified by achievement of K/DOQI targets with mortality and overall cardiovascular hospitalization. Third, to characterize the longitudinal changes in bone mineral markers. As part of this objective, we will describe the patterns and predictors of bone mineral markers and achievement, with K/DOQI targets, using repeated measurements on individuals over time. SECONDARY OBJECTIVES: First, To estimate the association of bone mineral markers (PTH, Ca, P and CaxP) classified by achievement of K/DOQI targets with specific cardiovascular outcomes, parathyroidectomy, manifest bone disease (including incidence of symptomatic bone fractures), hospitalizations and vascular access. Second, to evaluate the additional value of albumin and hemoglobin levels in conjunction with bone mineral markers in the prediction of mortality and clinical events.

Published
2008
Full Text
View/download PDF

21. Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis

Author

Taskapan, H., Ersoy, F. F., Passadakis, P. S., Tam, P., Memmos, D. E., Katopodis, K. P., Gultekin, M., Çukurova Üniversitesi, and Ondokuz Mayıs Üniversitesi

Subjects
chronic renal failure, vitamin D deficiency, dialysis, serum 25(OH)D
Abstract

ersoy, fevzi/0000-0001-9722-1560; camsari, taner/0000-0001-8293-3688 WOS: 000241194700004 PubMed: 17063991 The aim of this study was to evaluate the prevalence of vitamin D deficiency in chronic renal failure (CRF) patients on peritoneal dialysis (PD) and to correlate the findings with various demographic and renal osteodystrophy markers. Method: This cross-sectional, multicenter study was carried out in 273 PD patients with a mean age of 61.7 +/- 10.9 years and mean duration of PD 3.3 +/- 2.2 years. It included 123 female and 150 male patients from 20 centers in Greece and Turkey, countries that are on the same latitude, namely, 36 - 42 degrees north. We measured 25(OH)D-3 and 1.25(OH)(2)D-3 levels and some other clinical and laboratory indices of bone mineral metabolism. Results: Of these 273 patients 92% (251 patients) had vitamin D deficiency i.e. serum 25(OH)D-3 levels less than 15 ng/ml, 119 (43.6%) had severe vitamin D deficiency i.e. serum 25(OH)D-3 levels, less than 5 ng/ml, 132 (48.4%) had moderate vitamin D deficiency i.e. serum 25(OH)D3 levels, 5 - 15 ng/ml, 12 (4.4%) vitamin D insufficiency i.e. serum 25(OH)D3 levels 15 - 30 ng/ml and only 10 (3.6%) had adequate vitamin D stores. We found no correlation between 25(OH)D-3 levels and PTH, serum albumin, bone alkaline phosphatase, P, and Ca x P. In multiple regression analyses, the independent predictors of 25(OH)D-3 were age, presence of diabetes (DM-CRF), levels of serum calcium and serum 1.25(OH)(2)D-3- Conclusion: We found a high prevalence (92%) of vitamin D deficiency in these 273 PD patients, nearly one half of whom had severe vitamin D deficiency. Vitamin D deficiency is more common in DM-CRF patients than in non-DM-CRF patients. Our findings suggest that these patients should be considered for vitamin D supplementation.

Published
2006

22. Body pain during daily activities in patients on peritoneal dialysis

Author

Taskapan, H, Ersoy, E, Passadakis, P, Tam, P, Memmos, D, Katopodis, K, Gultekin, M, and Ondokuz Mayıs Üniversitesi

Abstract

WOS: 000226695600002 Objective. To review the prevalence of body pain during daily activities in patients on peritoneal dialysis (PD) and to correlate it with various demographic and renal osteodystrophy markers such as calcium (Ca), phosphorus (P), intact parathyroid hormone (iPTH), and vitamin D-3 levels. Methods. A cross-sectional study was conducted involving 530 chronic PD patients (44.3 % female, 55.6 % male) from 24 centers in Canada, Greece, and Turkey. Pain severity scoring during daily activities was performed using the pain scoring table of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Results. The overall prevalence of pain was 52.9 % (61.3 % in females and 49.5 % in males, p < 0.05). Morning stiffness was reported by 23.6 % of the patients, and diminished range of movement by 20 %. The mean age, weight, and body mass index were higher in patients with pain than in those without (p < 0.05). There was no statistically significant difference between patients with pain and those without pain with respect to their mean serum iPTH, Ca, P, Ca x P, ionized Ca, or bone alkaline phosphatase levels (p > 0.05). Mean serum 25-hydroxyvitamin D-3 [25(OH)D-3] levels were lower in patients with pain compared to those without pain (p < 0.05). Conclusions. A high percentage of the PD patients (53 %) had body pain; iPTH levels and other biochemical parameters of renal osteodystrophy were not different between those with and without pain. Patients with pain had lower 25(OH)D-3 levels than did those without. Factors such as age, gender, obesity, and metabolic factors may interact to cause varying degrees of articular/bone pain in patients on PD. Since vitamin D deficiency aggravates the signs and symptoms of joint disease such as pain and stiffness, one should attempt to correct levels of 25(OH)D-3, as well as 1,25(OH)(2)D-3 levels, in these patients.

Published
2005

23. Correlation of superscan findings with clinical parameters in renal osteodystrophy of peritoneal dialysis patients

Author

Yakupoglu, U, Karayalcin, B, Passadakis, P, Tam, P, Memmos, D, Katopodis, K, Gultekin, M, and Ondokuz Mayıs Üniversitesi

Abstract

42nd Annual Meeting of the European-Renal-Association/European-Dialysis-and-Transplant-Association (ERA-EDTA) -- JUN 04-07, 2005 -- Istanbul, TURKEY ersoy, fevzi/0000-0001-9722-1560; Karayalcin, Binnur/0000-0001-5809-0369; WOS: 000234376902161 … European Renal Assoc, European Diaysis &Transplant Assoc

Published
2005

25. Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients

Author

Passadakis P, Ersoy F, Tam P, Memmos D, Siamopoulos K, Ozener C, Akçiçek F, taner camsari, Ates K, Ataman R, Vlachojannis J, Dombros N, Utas C, Akpolat T, Bozfakioglu S, Gg, Wu, Karayaylali I, Arinsoy T, Stathakis C, Yavuz M, Tsakiris D, Dimitriades A, Me, Yilmaz, Gültekin M, Karayalçin B, Challa A, Polat N, and Dg, Oreopoulos

Subjects
Male, Prostate-Specific Antigen/*blood, Prostatic Neoplasms/diagnosis, Peritoneal Dialysis, Calcitriol/*blood, Prostate, Calcifediol/*blood, Prostatic Neoplasms, Prostate-Specific Antigen, Middle Aged, Alkaline Phosphatase, Sensitivity and Specificity, Tumor Markers, Biological/blood, Cross-Sectional Studies, Calcitriol, Parathyroid Hormone, Parathyroid Hormone/blood, Biomarkers, Tumor, Humans, Alkaline Phosphatase/blood, Prostate/enzymology, Calcifediol, Aged
Abstract

Measuring the free:total ratio of prostate-specific antigen (f/t-PSA) can improve the specificity of single-serum PSA values, distinguishing between benign prostatic hyperplasia (BPH) and prostatic carcinoma (PCa) in men over the age of 50. Additionally, clinical trials have shown that dihydroxyvitamin D3 can slow the rate of PSA rise in PCa patients. However, little is known regarding the applicability of those findings in men undergoing chronic peritoneal dialysis (CPD). In the present study, we investigated the prevalence of increased serum PSA levels among CPD patients and correlated those values with serum levels of vitamin D [25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3]. We undertook a cross-sectional study of 71 male CPD patients without a known history of prostate cancer from 24 centers in Canada, Greece, and Turkey. All of the patients were more than 50 years of age. In these patients, we measured serum concentrations of PSA, free PSA (f-PSA), total PSA (t-PSA), prostate alkaline phosphatase (PAP), 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3, and intact parathyroid hormone (iPTH). We recorded serum PSA levels < 4 ng/mL in 62 patients (87.3%, group A) and levels > 4 ng/mL in 9 patients (12.7%, group B). The f/t-PSA ratio was < 0.25 in 16 patients (22.5%). Group B patients were older than those in group A (median: 73 years vs. 65 years, p < 0.01) and had a lower body weight (median: 66.5 kg vs. 76.7 kg, p < 0.05). We observed no statistically significant difference between the two groups for serum 1,25-dihydroxyvitamin D3 (median: 9.8 ng/mL vs. 10.1 ng/mL) or 25-hydroxyvitamin D3 (8 ng/mL vs. 8.2 ng/mL) levels. Also, we observed no correlation between vitamin D levels and f/t-PSA, but iPTH levels were significantly higher in group A (200.5 pg/mL vs. 61.2 pg/mL, p < 0.04). Also, serum PAP levels correlated significantly with PSA (r = 0.49, p = 0.01) and with f-PSA (r = 0.56, p = 0.000). Our results showed no clear relationship between vitamin D and serum levels of PSA or-of f/t-PSA in PD patients. However, further studies are needed to better define the uses of these PSA markers in PD patients because, in such patients, other relevant factors might be implicated in their predictive value. Adv Perit Dial

Published
2004

26. Pathophysiology and clinical studies in CKD 5D

Author

Raimann, J. G., primary, Gotch, F., additional, Keen, M., additional, Kotanko, P., additional, Levin, N. W., additional, Pierratos, A., additional, Lindsay, R., additional, Severova-Andreevska, G., additional, Trajceska, L., additional, Gelev, S., additional, Selim, G., additional, Sikole, A., additional, Yoon, S. Y., additional, Hwang, S. D., additional, Cho, D. K., additional, Cho, Y. H., additional, Moon, S. J., additional, Ribitsch, W., additional, Schreiner, P. J., additional, Uhlmann, M., additional, Schilcher, G., additional, Stadlbauer, V., additional, Horina, J. H., additional, Rosenkranz, A. R., additional, Schneditz, D., additional, Kiss, I., additional, Kerkovits, L., additional, Ambrus, C., additional, Kulcsar, I., additional, Szegedi, J., additional, Benke, A., additional, Borbas, B., additional, Ferenczi, S., additional, Hengsperger, M., additional, Kazup, S., additional, Nagy, L., additional, Nemeth, J., additional, Rozinka, A., additional, Szabo, T., additional, Szelestei, T., additional, Toth, E., additional, Varga, G., additional, Wagner, G., additional, Zakar, G., additional, Gergely, L., additional, Tisler, A., additional, Kiss, Z., additional, Sasaki, S., additional, Miyamato, M., additional, Nomura, A., additional, Koitabashi, K., additional, Nishiwaki, H., additional, Suzuki, T., additional, Uchida, D., additional, Kawarazaki, H., additional, Shibagaki, Y., additional, Kimura, K., additional, Libetta, C., additional, Martinelli, C., additional, Margiotta, E., additional, Borettaz, I., additional, Canevari, M., additional, Esposito, P., additional, Sepe, V., additional, Dal Canton, A., additional, Pateinakis, P., additional, Dimitriadis, C., additional, Papagianni, A., additional, Douma, S., additional, Efstratiadis, G., additional, Memmos, D., additional, Nelson, C. L., additional, Dunstan, P. J., additional, Zwiech, R., additional, Hasuike, Y., additional, Yanase, K., additional, Hamahata, S., additional, Nagai, T., additional, Yahiro, M., additional, Kaibe, S., additional, Kida, A., additional, Nagasawa, Y., additional, Kuragano, T., additional, Nakanishi, T., additional, Kim, J. S., additional, Yang, J. W., additional, Choi, S. O., additional, Han, B. G., additional, Chang, J. H., additional, Kim, A. J., additional, Kim, H. S., additional, Ro, H., additional, Jung, J. Y., additional, Lee, H. H., additional, Chung, W., additional, Tanaka, H., additional, Kita, T., additional, Okamoto, K., additional, Mikami, M., additional, Sakai, R., additional, Lojacono, E., additional, Votta, B., additional, Rampino, T., additional, Gregorini, M., additional, Amore, A., additional, Coppo, R., additional, ElSharkawy, M. M. S., additional, Kamel, M., additional, Elhamamsy, M., additional, Allam, S., additional, Ryu, J.-H., additional, Lee, S., additional, Hong, S. C., additional, Kim, S.-J., additional, Kang, D.-H., additional, Ryu, D.-R., additional, Choi, K. B., additional, Kiraz, T., additional, Yalcin, A., additional, Akay, M., additional, Sahin, G., additional, Musmul, A., additional, Kamijo, Y., additional, Horiuchi, H., additional, Iida, H., additional, Saito, K., additional, Furutera, R., additional, Ishibashi, Y., additional, Sidiropoulou, M., additional, Patsialas, S., additional, Angelopoulos, M., additional, Torreggiani, M., additional, Serpieri, N., additional, Arazzi, M., additional, Esposito, V., additional, Calatroni, M., additional, La Porta, E., additional, Catucci, D., additional, Montagna, G., additional, Semeraro, L., additional, Efficace, E., additional, Piazza, V., additional, Picardi, L., additional, Villa, G., additional, Esposito, C., additional, Kim, J. C., additional, Hwang, E., additional, Park, K., additional, Karakizlis, H., additional, Bohl, K., additional, Kortus-Goetze, B., additional, Dodel, R., additional, Hoyer, J., additional, Cinar, A., additional, Kazancioglu, R., additional, Isik, A. T., additional, Aydemir, E., additional, Gorcin, B., additional, Radic, J., additional, Ljutic, D., additional, Radic, M., additional, Kovacic, V., additional, Sain, M., additional, Dodig Curkovic, K., additional, Grzegorzewska, A. E., additional, Niepolski, L., additional, Sikora, J., additional, Jagodzinski, P., additional, Sowinska, A., additional, Sirolli, V., additional, Rossi, C., additional, Di Castelnuovo, A., additional, Felaco, P., additional, Amoroso, L., additional, Zucchelli, M., additional, Ciavardelli, D., additional, Sacchetta, P., additional, Urbani, A., additional, Arduini, A., additional, Bonomini, M., additional, Inoue, T., additional, Okano, K., additional, Tsuruta, Y., additional, Tsuchiya, K., additional, Akiba, T., additional, Nitta, K., additional, and Pajzderski, D., additional

Published
2013
Full Text
View/download PDF

28. Primary and secondary glomerulonephritis II

Author

Valdivia Vega, R. P., primary, Perez Carlos, J., additional, LI, X., additional, Xu, X., additional, Zhang, W., additional, Ren, H., additional, Chen, N., additional, Yorioka, N., additional, Doi, T., additional, Hirashio, S., additional, Arita, M., additional, Hirabayashi, A., additional, Tilkiyan, E., additional, Chonova, E., additional, Ronchev, Y., additional, Kumchev, E., additional, Giamalis, P., additional, Spartalis, M., additional, Stangou, M., additional, Tsouchnikas, I., additional, Moysiades, D., additional, Dimopoulou, D., additional, Garyfalos, A., additional, Efstratiadis, G., additional, Memmos, D., additional, Schonermarck, U., additional, Eichhorn, P., additional, Sitter, T., additional, Wendler, T., additional, Vielhauer, V., additional, Lederer, S., additional, Fechner, K., additional, Fischereder, M., additional, Bantis, C., additional, Heering, P., additional, Kouri, N.-M., additional, Schwandt, C., additional, Kuhr, N., additional, Ivens, K., additional, Rump, L.-C., additional, Matta, V., additional, Melis, P., additional, Conti, M., additional, Cao, R., additional, Binda, V., additional, Altieri, P., additional, Asunis, A. M., additional, Catani, W., additional, Floris, M., additional, Angioi, A., additional, Congia, M., additional, Cucca, F., additional, Minerba, L., additional, Peri, M., additional, Pani, A., additional, Beck, L. H., additional, Fervenza, F. C., additional, Bomback, A. S., additional, Ayalon, R., additional, Irazabal, M. V., additional, Eirin, A., additional, Cattran, D. C., additional, Appel, G. B., additional, Salant, D. J., additional, Santoro, D., additional, Postorino, A., additional, Costantino, G., additional, Bellinghieri, G., additional, Savica, V., additional, Weiner, M., additional, Goh, S. M., additional, Mohammad, A., additional, Eriksson, P., additional, Westman, K., additional, Selga, D., additional, Salama, A., additional, Segelmark, M., additional, Chocova, Z., additional, Hruskova, Z., additional, Mareckova, H., additional, Svobodova, B., additional, Jancova, E., additional, Bednarova, V., additional, Rysava, R., additional, Tesar, V., additional, Hanzal, V., additional, Zamboch, K., additional, Grussmannova, M., additional, Svojanovsky, J., additional, Klaboch, J., additional, Kubisova, M., additional, Sevcik, J., additional, Olsanska, R., additional, Sobotkova, M., additional, Becvar, R., additional, Nemec, P., additional, Kodeda, M., additional, Jilek, D., additional, Hussain, M., additional, Dhaygude, A., additional, Cartery, C., additional, Huart, A., additional, Plaisier, E., additional, Bongard, V., additional, Montastruc, F., additional, Ronco, P., additional, Pourrat, J., additional, Chauveau, D., additional, Prasad, N., additional, Gurjar, D., additional, Bhadauria, D., additional, Sharma, R. K., additional, Gupta, A., additional, Kaul, A., additional, Jain, M., additional, Venning, M., additional, Brown, N., additional, Bruce, I., additional, Noor, S., additional, Bekker, P., additional, Potarca, A., additional, Dairaghi, D., additional, Miao, S., additional, Powers, J. P., additional, Jaen, J. C., additional, Schall, T. J., additional, Kalavrizioti, D., additional, Gerolymos, M., additional, Komninakis, D., additional, Rodi, M., additional, Mouzaki, A., additional, Kalliakmani, P., additional, Goumenos, D., additional, Choi, B. S., additional, Park, C. W., additional, Kim, Y.-S., additional, Yang, C. W., additional, Sun, I. O., additional, Qin, W., additional, Xie, L., additional, Tan, C., additional, Mian, W., additional, Fu, P., additional, Kaminskyy, V., additional, Hao, X., additional, Wang, W., additional, Cengiz, C., additional, Nur, C., additional, Nurdan, Y., additional, Selman, G., additional, Pinar, T., additional, Mehmet, T., additional, Lale, S., additional, Caliskan, S., additional, Shinzawa, M., additional, Yamamoto, R., additional, Nagasawa, Y., additional, Oseto, S., additional, Mori, D., additional, Niihata, K., additional, Fukunaga, M., additional, Yamauchi, A., additional, Tsubakihara, Y., additional, Rakugi, H., additional, Isaka, Y., additional, Chen, J.-S., additional, Lin, Y.-F., additional, Lin, W.-Y., additional, Shu, K.-H., additional, Chen, H.-H., additional, Wu, C.-J., additional, Yang, C.-S., additional, Tseng, T.-L., additional, Zaza, G., additional, Bernich, P., additional, Lupo, A., additional, Panizo, N., additional, Rivera, F., additional, Lopez Gomez, J. M., additional, Regn, S. R. o. G., additional, Ceresini, G., additional, Vaglio, A., additional, Urban, M. L., additional, Corradi, D., additional, Usberti, E., additional, Palmisano, A., additional, Buzio, C., additional, Zineb, H., additional, Ramdani, B., additional, Marques, L. P. J., additional, Rioja, L. D. S., additional, Rocco, R., additional, Nery, A. C. F., additional, Novaes, B. C., additional, Bridoux, F., additional, Sicard, A., additional, Labatut, D., additional, Touchard, G., additional, Sarkozy, C., additional, Vanhille, P., additional, Callard, P., additional, Essig, M., additional, Provot, F., additional, Nony, A., additional, Karras, A., additional, Agustin, C. P., additional, M Belen, H. R., additional, Carmen, C. P., additional, Eliana, O., additional, Elisa, P., additional, Luis, P., additional, Alberto, M.-C., additional, Javier, N., additional, Isabel, F., additional, Atzeni, A., additional, Fois, A., additional, Piras, D., additional, Maxia, S., additional, Sau, G., additional, Pili, G., additional, Porcu, M., additional, Derudas, D., additional, Angelucci, E., additional, Ledda, A., additional, La Nasa, G., additional, Ossareh, S., additional, Asgari, M., additional, Savaj, S., additional, Ataipour, Y., additional, Abdi, E., additional, Malakoutian, T., additional, Rajaa, R., additional, Berkchi, F. Z., additional, Haffane, L., additional, Squalli, Z., additional, Rouass, L., additional, Al Hamany, Z., additional, Ezzaitouni, F., additional, Benamar, L., additional, Bayahya, R., additional, Ouzeddoun, N., additional, Gao-Yuan, H., additional, Yao, X., additional, Xin, C., additional, Zhen, C., additional, Yong-Chun, G., additional, Qing-Wen, W., additional, Hui-Ping, C., additional, Da-XI, J., additional, De-Hua, G., additional, Wei-Xin, H., additional, Zhi-Hong, L., additional, Fatima Zahra, B., additional, Laila, H., additional, Zoubair, S., additional, Naima, O., additional, Smykal-Jankowiak, K., additional, Niemir, Z., additional, Polcyn-Adamczak, M., additional, Szramka-Pawlak, B., additional, Zaba, R., additional, Zhang, C., additional, MA, Y., additional, Shen, P., additional, Ouyang, Y., additional, Pan, X., additional, Wang, Z., additional, Feng, X., additional, and Ni, L., additional

Published
2012
Full Text
View/download PDF

29. Cardiovascular complications in CKD 5D

Author

Fusaro, M., primary, Fusaro, M., additional, Noale, M., additional, Tripepi, G., additional, D'angelo, A., additional, Miozzo, D., additional, Gallieni, M., additional, Study Group, P.-V., additional, Tsamelesvili, M., additional, Dimitriadis, C., additional, Papagianni, A., additional, Raidis, C., additional, Efstratiadis, G., additional, Memmos, D., additional, Mutluay, R., additional, Konca Degertekin, C., additional, Derici, U., additional, Deger, S. M., additional, Akkiyal, F., additional, Gultekin, S., additional, Gonen, S., additional, Tacoy, G., additional, Arinsoy, T., additional, Sindel, S., additional, Sanchez-Perales, C., additional, Vazquez, E., additional, Merino, E., additional, Perez Del Barrio, P., additional, Borrego, F. J., additional, Borrego, M. J., additional, Liebana, A., additional, Krzanowski, M., additional, Janda, K., additional, Dumnicka, P., additional, Krasniak, A., additional, Sulowicz, W., additional, Kim, Y.-O., additional, Yoon, S.-A., additional, Yun, Y.-S., additional, Song, H.-C., additional, Kim, B.-S., additional, Cheong, M. A., additional, Pasch, A., additional, Farese, S., additional, Floege, J., additional, Jahnen-Dechent, W., additional, Ohtake, T., additional, Furuya, R., additional, Iwagami, M., additional, Tsutsumi, D., additional, Mochida, Y., additional, Ishioka, K., additional, Oka, M., additional, Maesato, K., additional, Moriya, H., additional, Hidaka, S., additional, Kobayashi, S., additional, Guedes, A., additional, Malho Guedes, A., additional, Pinho, A., additional, Fragoso, A., additional, Cruz, A., additional, Mendes, P., additional, Morgado, E., additional, Bexiga, I., additional, Silva, A. P., additional, Neves, P., additional, Oyake, N., additional, Suzuki, K., additional, Itoh, S., additional, Yano, S., additional, Turkmen, K., additional, Kayikcioglu, H., additional, Ozbek, O., additional, Saglam, M., additional, Toker, A., additional, Tonbul, H. Z., additional, Gelev, S., additional, Trajceska, L., additional, Srbinovska, E., additional, Pavleska, S., additional, Amitov, V., additional, Selim, G., additional, Dzekova, P., additional, Sikole, A., additional, Bouarich, H., additional, Lopez, S., additional, Alvarez, C., additional, Arribas, I., additional, DE Sequera, P., additional, Rodriguez, D., additional, Tanaka, S., additional, Kanemitsu, T., additional, Sugahara, M., additional, Kobayashi, M., additional, Uchida, L., additional, Ishimoto, Y., additional, Kotera, N., additional, Tanimoto, S., additional, Tanabe, K., additional, Hara, K., additional, Sugimoto, T., additional, Mise, N., additional, Goldstein, B., additional, Turakhia, M., additional, Arce, C., additional, Winkelmayer, W., additional, Zayed, B. E.-D., additional, Said, K., additional, Nishimura, M., additional, Okamoto, Y., additional, Tokoro, T., additional, Nishida, M., additional, Hashimoto, T., additional, Iwamoto, N., additional, Takahashi, H., additional, Ono, T., additional, Sato, N., additional, Raimann, J., additional, Usvyat, L. A., additional, Sands, J., additional, Levin, N. W., additional, Kotanko, P., additional, Iwasaki, M., additional, Joki, N., additional, Tanaka, Y., additional, Ikeda, N., additional, Hayashi, T., additional, Kubo, S., additional, Imamura, T.-A., additional, Takahashi, Y., additional, Hirahata, K., additional, Imamura, Y., additional, Hase, H., additional, Claes, K., additional, Meijers, B., additional, Bammens, B., additional, Kuypers, D., additional, Naesens, M., additional, Vanrenterghem, Y., additional, Evenepoel, P., additional, Boscutti, G., additional, Calabresi, L., additional, Bosco, M., additional, Simonelli, S., additional, Boer, E., additional, Vitali, C., additional, Martone, M., additional, Mattei, P. L., additional, Franceschini, G., additional, Baligh, E., additional, El-Shafey, E., additional, Ezaat, A., additional, Zawada, A., additional, Rogacev, K., additional, Hummel, B., additional, Grun, O., additional, Friedrich, A., additional, Rotter, B., additional, Winter, P., additional, Geisel, J., additional, Fliser, D., additional, Heine, G. H., additional, Makino, J.-I., additional, Makino, K.-S., additional, Ito, T., additional, Genovesi, S., additional, Santoro, A., additional, Fabbrini, P., additional, Rossi, E., additional, Pogliani, D., additional, Stella, A., additional, Bonforte, G., additional, Remuzzi, G., additional, Bertoli, S., additional, Pozzi, C., additional, Pasquali, S., additional, Cagnoli, L., additional, Conte, F., additional, Buzadzic, I., additional, Tosic, J., additional, Dimkovic, N., additional, Djuric, Z., additional, Popovic, J., additional, Pejin Grubisa, I., additional, Barjaktarevic, N., additional, DI Napoli, A., additional, DI Lallo, D., additional, Salvatori, M. F., additional, Franco, F., additional, Chicca, S., additional, Guasticchi, G., additional, Onofriescu, M., additional, Hogas, S., additional, Luminita, V., additional, Mugurel, A., additional, Gabriel, V., additional, Laura, F., additional, Irina, M., additional, Adrian, C., additional, Bosch, E., additional, Baamonde, E., additional, Culebras, C., additional, Perez, G., additional, El Hayek, B., additional, Ramirez, J. I., additional, Ramirez, A., additional, Garcia, C., additional, Lago, M., additional, Toledo, A., additional, Checa, M. D., additional, Taira, T., additional, Hirano, T., additional, Nohtomi, K., additional, Hyodo, T., additional, Chiba, T., additional, Saito, A., additional, Kim, Y. K., additional, Choi, E. J., additional, Yang, C. W., additional, Kim, Y.-S., additional, Lim, P. S., additional, Ming Ying, W., additional, Ya-Chung, J., additional, Zaripova, I., additional, Kayukov, I., additional, Essaian, A., additional, Nimgirova, A., additional, Young, H., additional, Dungey, M., additional, Watson, E. L., additional, Baines, R., additional, Burton, J. O., additional, Smith, A. C., additional, Yamazaki, K., additional, Bossola, M., additional, Colacicco, L., additional, Scribano, D., additional, Vulpio, C., additional, Tazza, L., additional, Okada, T., additional, Okada, N., additional, Michibata, I., additional, Yura, T., additional, Montero, N., additional, Soler, M., additional, Pascual, M., additional, Barrios, C., additional, Marquez, E., additional, Rodriguez, E., additional, Orfila, M. A., additional, Cao, H., additional, Arcos, E., additional, Comas, J., additional, Pascual, J., additional, Ferrario, M., additional, Garzotto, F., additional, Sironi, T., additional, Monacizzo, S., additional, Basso, F., additional, Cruz, D. N., additional, Moissl, U., additional, Tetta, C., additional, Signorini, M. G., additional, Cerutti, S., additional, Ronco, C., additional, Mostovaya, I., additional, Grooteman, M., additional, Van den Dorpel, M., additional, Penne, L., additional, Van der Weerd, N., additional, Mazairac, A., additional, Den Hoedt, C., additional, Levesque, R., additional, Nube, M., additional, Ter Wee, P., additional, Bots, M., additional, Blankestijn, P., additional, Liu, J., additional, MA, K. L., additional, Zhang, X., additional, Liu, B. C., additional, Vladu, I.-D., additional, Mustafa, R., additional, Cana-Ruiu, D., additional, Vaduva, C., additional, Grauntanu, C., additional, Mota, E., additional, Singh, R., additional, Abbasian, N., additional, Stover, C., additional, Brunskill, N., additional, Burton, J., additional, Herbert, K., additional, Bevington, A., additional, Wu, M., additional, Tang, R.-N., additional, Gao, M., additional, Liu, H., additional, Chen, L., additional, LV, L.-L., additional, Liu, B.-C., additional, Nikodimopoulou, M., additional, Liakos, S., additional, Kapoulas, S., additional, Karvounis, C., additional, Fedak, D., additional, Kuzniewski, M., additional, Paulina, D., additional, Kusnierz-Cabala, B., additional, Kapusta, M., additional, Solnica, B., additional, Junque, A., additional, Vicent, E. S., additional, Moreno, L., additional, Fulquet, M., additional, Duarte, V., additional, Saurina, A., additional, Pou, M., additional, Macias, J., additional, Lavado, M., additional, Ramirez de Arellano, M., additional, Ryuzaki, M., additional, Nakamoto, H., additional, Kinoshita, S., additional, Kobayashi, E., additional, Takimoto, C., additional, Shishido, T., additional, Enia, G., additional, Torino, C., additional, Tripepi, R., additional, Panuccio, V., additional, Postorino, M., additional, Clementi, A., additional, Garozzo, M., additional, Bonanno, G., additional, Boito, R., additional, Natale, G., additional, Cicchetti, T., additional, Chippari, A., additional, Logozzo, D., additional, Alati, G., additional, Cassani, S., additional, Sellaro, A., additional, Zoccali, C., additional, Quiroga, B., additional, Verde, E., additional, Abad, S., additional, Vega, A., additional, Goicoechea, M., additional, Reque, J., additional, Lopez-Gomez, J. M., additional, Luno, J., additional, Cabre Menendez, C., additional, Moles, V., additional, Vives, J. P., additional, Villa, D., additional, Vinas, J., additional, Compte, T., additional, Arruche, M., additional, Diaz, C., additional, Soler, J., additional, Aguilera, J., additional, Martinez Vea, A., additional, De Mauri, A., additional, David, P., additional, Conte, M. M., additional, Chiarinotti, D., additional, Ruva, C. E., additional, De Leo, M., additional, Bargnoux, A.-S., additional, Morena, M., additional, Jaussent, I., additional, Chalabi, L., additional, Bories, P., additional, Dion, J.-J., additional, Henri, P., additional, Delage, M., additional, Dupuy, A.-M., additional, Badiou, S., additional, Canaud, B., additional, Cristol, J.-P., additional, Sironi, E., additional, Pieruzzi, F., additional, Galbiati, E., additional, Vigano, M. R., additional, Anpalakhan, S., additional, Rocha, S., additional, Chitalia, N., additional, Sharma, R., additional, Kaski, J. C., additional, Chambers, J., additional, Goldsmith, D., additional, Banerjee, D., additional, Cernaro, V., additional, Lacquaniti, A., additional, Lupica, R., additional, Lucisano, S., additional, Fazio, M. R., additional, Donato, V., additional, Buemi, M., additional, Segalen, I., additional, Vinsonneau, U., additional, Tanquerel, T., additional, Quiniou, G., additional, Le Meur, Y., additional, Seibert, E., additional, Girndt, M., additional, Zohles, K., additional, Ulrich, C., additional, Kluttig, A., additional, Nuding, S., additional, Swenne, C., additional, Kors, J., additional, Werdan, K., additional, Fiedler, R., additional, Van der Weerd, N. C., additional, Grooteman, M. P., additional, Van den Dorpel, M. A., additional, Nube, M. J., additional, Wetzels, J., additional, Swinkels, D. W., additional, Ter Wee, P. M., additional, Khandekar, A., additional, Khandge, J., additional, Lee, J. E., additional, Moon, S. J., additional, Choi, K. H., additional, Lee, H. Y., additional, Kim, B. S., additional, Tuaillon, E., additional, Rodriguez, A., additional, Chenine, L., additional, Vendrell, J.-P., additional, Sue, Y.-M., additional, Tang, C.-H., additional, Chen, Y.-C., additional, Segura, P., additional, Garcia Cortes, M. J., additional, Gil, J. M., additional, Biechy, M. M., additional, Poulikakos, D., additional, Shah, A., additional, Persson, M., additional, Dattolo, P., additional, Amidone, M., additional, Michelassi, S., additional, Moriconi, L., additional, Betti, G., additional, Conti, P., additional, Rosati, A., additional, Mannarino, A., additional, Panichi, V., additional, Pizzarelli, F., additional, Klejna, K., additional, Naumnik, B., additional, Koc-Zorawska, E., additional, Mysliwiec, M., additional, Dimitrie, S., additional, Simona, H., additional, Mihaela, O., additional, Gabriela, O., additional, Radu, S., additional, Octavian, P., additional, Akdam, H., additional, Akar, H., additional, Yenicerioglu, Y., additional, Kucuk, O., additional, Kurt Omurlu, I., additional, Thambiah, S., additional, Roplekar, R., additional, Manghat, P., additional, Fogelman, I., additional, Fraser, W., additional, Hampson, G., additional, Likaj, E., additional, Caco, G., additional, Seferi, S., additional, Rroji, M., additional, Barbullushi, M., additional, Thereska, N., additional, Serban, A., additional, Carmen, V., additional, Cristian, S., additional, Silvia, L., additional, and Covic, A., additional

Published
2012
Full Text
View/download PDF

30. Mineral and bone disease - CKD 5D

Author

Hecking, M., primary, Kainz, A., additional, Bielesz, B., additional, Plischke, M., additional, Beilhack, G., additional, Hoerl, W. H., additional, Sunder-Plassmann, G., additional, Bieglmayer, C., additional, Benchetrit, S., additional, Green, J., additional, Bernheim, J., additional, Golan, E., additional, Oyake, N., additional, Suzuki, K., additional, Itoh, S., additional, Tanabe, K., additional, Fujimori, A., additional, Okada, S., additional, Yamamoto, K., additional, Sakai, M., additional, Kamiura, N., additional, Solenne, P., additional, Guebre-Egziabher, F., additional, Bacchetta, J., additional, Drai, J., additional, Richard, M., additional, Chapurlat, R., additional, Fouque, D., additional, Nowak, Z., additional, Grzegorz, K., additional, Maria, K., additional, Zofia, W., additional, Zamboch, K., additional, Zahalkova, J., additional, Kosatikova, Z., additional, Skypalova, P., additional, Skarda, J., additional, Cunha, J., additional, Boim, M., additional, Ferreira, V., additional, Naves, M., additional, Kikuchi, H., additional, Shimada, H., additional, Takimoto, Y., additional, Karasawa, R., additional, Shimotori, M., additional, Ikarashi, K., additional, Saito, N., additional, Miyazaki, S., additional, Sakai, S., additional, Suzuki, M., additional, Ogata, H., additional, Takeshima, A., additional, Yamamoto, M., additional, Asakura, K., additional, Kato, T., additional, Shishido, K., additional, Koiwa, F., additional, Mizobuchi, M., additional, Kinugasa, E., additional, Akizawa, T., additional, Londrino, F., additional, Corbani, V., additional, Ardini, M., additional, Falqui, V., additional, Zattera, T., additional, Rombola', G., additional, Takeshige, Y., additional, Matsuzaka, K., additional, Ciceri, P., additional, Volpi, E., additional, Brenna, I., additional, Elli, F., additional, Borghi, E., additional, Brancaccio, D., additional, Cozzolino, M., additional, Farrand, K., additional, Copley, J. B., additional, Heise, J., additional, Fridman, M., additional, Keith, M., additional, Silverberg, A., additional, Wilson, R., additional, Poole, L., additional, Jean, G., additional, Bresson, E., additional, Chazot, C., additional, Maduell, F., additional, Arias, M., additional, Sentis, A., additional, Rodriguez, N., additional, Jimenez, S., additional, Alemany, B., additional, Perez, N., additional, Vera, M., additional, Fontsere, N., additional, Carrera, M., additional, Cases, A., additional, Sonikian, M., additional, Miha, T., additional, Skarakis, I., additional, Karatzas, I., additional, Karaitianou, A., additional, Tomanoski, V., additional, Petkovic, D., additional, Curic, I., additional, Hrvacevic, R., additional, Kaperonis, N., additional, Kourvelou, C., additional, Sgantzos, A., additional, Nastou, D., additional, Ntatsis, G., additional, Ziakka, S., additional, Karakasis, F., additional, Nikolopoulos, V., additional, Zoubaniotou, D., additional, Koutsovasili, A., additional, Zagorianakos, A., additional, Kolovos, V., additional, Papagalanis, N., additional, Forni, V., additional, Pruijm, M., additional, Tousset, E., additional, Zweiacker, C., additional, Menetrey, I., additional, Berwert, L., additional, Bullani, R., additional, Cherpillod, A., additional, Gabutti, L., additional, Gauthier, T., additional, Halabi, G., additional, Mathieu, C., additional, Meier, P., additional, Phan, O., additional, Pianca, S., additional, Schoenholzer, C., additional, Teta, D., additional, Von Albertini, B., additional, Vrijens, B., additional, Burnier, M., additional, Kurita, N., additional, Fukagawa, M., additional, Onishi, Y., additional, Yamaguchi, T., additional, Hasegawa, T., additional, Fukuma, S., additional, Kurokawa, K., additional, Fukuhara, S., additional, Urena, P., additional, Bridges, I., additional, Christiano, C., additional, Cournoyer, S., additional, Cooper, K., additional, Farouk, M., additional, Kopyt, N., additional, Rodriguez, M., additional, Zehnder, D., additional, Covic, A., additional, Tominaga, Y., additional, Hiramitsu, T., additional, Yamamoto, T., additional, Nanmoku, K., additional, Matsuda, Y., additional, Tsuzuki, T., additional, Lang, C.-L., additional, Lu, K.-C., additional, Wang, M.-H., additional, Liu, S.-Y., additional, Huang, J.-W., additional, Chiang, C.-K., additional, Hung, K.-Y., additional, Bantis, C., additional, Kouri, N.-M., additional, Tsandekidou, E., additional, Frangidis, S., additional, Tsiandoulas, A., additional, Liakou, E., additional, Bamichas, G., additional, Stangou, M., additional, Papagianni, A., additional, Efstratiadis, G., additional, Natse, T., additional, Memmos, D., additional, Messa, P., additional, Cannella, G., additional, Mazzaferro, S., additional, Yu, X., additional, Bieber, B., additional, Guidinger, M., additional, Yang, X., additional, Tentori, F., additional, Pisoni, R., additional, Qian, J., additional, Chen, N., additional, Yan, Y., additional, Wang, M., additional, Zuo, L., additional, Wang, H., additional, Albert, J., additional, Ramirez, S., additional, Caccetta, F., additional, Caroppo, M., additional, Musio, F., additional, Mudoni, A., additional, Accogli, A., additional, Zacheo, M. D., additional, Nuzzo, V., additional, Selim, G., additional, Stojceva-Taneva, O., additional, Tozija, L., additional, Gelev, S., additional, Pusevski, V., additional, Dzekova-Vidimliski, P., additional, Rambabova-Busletic, I., additional, Sikole, A., additional, Esposito, P., additional, Coppo, R., additional, Malberti, F., additional, Dal Canton, A., additional, Moriwaki, K., additional, Komaba, H., additional, Kakuta, T., additional, Cernaro, V., additional, Lupica, R., additional, Donato, V., additional, Lacquaniti, A., additional, Fazio, M. R., additional, Lucisano, S., additional, Buemi, M., additional, Okuno, S., additional, Ishimura, E., additional, Tsuboniwa, N., additional, Norimine, K., additional, Yamakawa, K., additional, Yamakawa, T., additional, Shoji, S., additional, Mori, K., additional, Nishizawa, Y., additional, Inaba, M., additional, Dahaba, M., additional, Seck, S., additional, Cisse, M., additional, Jotoku, Y., additional, Sato, Y., additional, Dimkovic, N., additional, Asicioglu, E., additional, Kahveci, A., additional, Arikan, H., additional, Koc, M., additional, Tuglular, S., additional, Ozener, C., additional, Kido, R., additional, Yamaguch, T., additional, Krasniak, A., additional, Drozdz, M., additional, Chmiel, G., additional, Podolec, P., additional, Pasowicz, M., additional, Kowalczyk-Michalek, M., additional, Sulowicz, W., additional, Perez-Suarez, G., additional, Baamonde, E., additional, Bosch, E., additional, Ramirez, J. I., additional, El Hayek, B., additional, Lago, M. D. M., additional, Garcia, C., additional, Checa, M. D., additional, Hiramatsu, R., additional, Ubara, Y., additional, Salas, K., additional, Vicent, E. S., additional, Gonzalez Oliva, J. C., additional, Fulquet, M., additional, Duarte, V., additional, Pou, M., additional, Saurina, A., additional, Macias, J., additional, Ramirez de Arellano, M., additional, Matias, P., additional, Jorge, C., additional, Mendes, M., additional, Amaral, T., additional, Ferreira, C., additional, Aires, I., additional, Gil, C., additional, Ferreira, A., additional, Arcal, C., additional, Campistol, J. M., additional, Seferi, S., additional, Rroji, M., additional, Likaj, E., additional, Petrela, E., additional, Barbullushi, M., additional, Zeneli, N., additional, Mumajesi, S., additional, Thereska, N., additional, Vulpio, C., additional, Bossola, M., additional, Stigliano, E., additional, Fadda, G., additional, Gueiros, A. P. S., additional, Borba Junior, J. O., additional, Lordsllen, A. B. d. M. D. S., additional, Gueiros, J. E. d. B., additional, Itami, N., additional, Tuneyama, K., additional, Uemura, S., additional, Hamada, H., additional, Takada, J., additional, Takahashi, K., additional, Adamidis, K., additional, Apostolou, T., additional, Pleros, C., additional, Oikonomaki, T., additional, Kyratzi, E., additional, Exarchos, D., additional, Metaxatos, G., additional, Dracopoulos, S., additional, Nikolopoulou, N., additional, Delanaye, P., additional, Dubois, B., additional, Krzesinski, J.-M., additional, Cavalier, E., additional, De la Fuente, V., additional, Gil, M. T., additional, Gutierrez, P., additional, Delgado, P., additional, Ribero, J., additional, Arenas, L., additional, Sezer, S., additional, Tutal, E., additional, Bal, Z., additional, Erkmen Uyar, M., additional, Ozdemir Acar, F. N., additional, Azevedo de Oliveira, R., additional, Carvalho Barreto, F., additional, Dos Reis, L., additional, Cunha Ferreira, J., additional, Maria Leme Britto, Z., additional, Maria Moyses, R., additional, Jorgetti, V., additional, Ozelsancak, R., additional, Gurlek Demirci, B., additional, Torun, D., additional, Veljancic, L., additional, Radojevic, M., additional, Paunic, Z., additional, Vavic, N., additional, Obrencevic, K., additional, Kovacevic, Z., additional, and Pejovic, J., additional

Published
2012
Full Text
View/download PDF

44. Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series.

Author

Bantis C, Stangou M, Schlaugat C, Alexopoulos E, Pantzaki A, Memmos D, Ivens K, and Heering PJ

Abstract

BACKGROUND: There are few anecdotal reports of circulating antineutrophil cytoplasmic autoantibodies (ANCAs) in patients with immunoglobulin A (IgA) nephropathy. STUDY DESIGN: Retrospective case series. SETTING & PARTICIPANTS: We studied 8 patients with crescentic IgA nephropathy associated with ANCAs against myeloperoxidase (n = 5) and proteinase 3 (n = 3) followed up for 2.4 +/- 1.7 years. They were compared with 26 patients with IgA nephropathy with > 10% crescentic glomeruli, but negative for ANCAs. OUTCOMES: We analyzed clinical and histologic features of patients and their response to treatment. MEASUREMENTS: Screening for ANCAs was performed using indirect immunofluorescence, and positive results were verified using enzyme-linked immunosorbent assay. RESULTS: All patients with crescentic IgA nephropathy and positive for ANCAs, compared with only one-third of ANCA-negative patients, presented with the clinical syndrome of rapid progressive glomerulonephritis. ANCA-positive patients reached a higher peak serum creatinine level within the first 3 months (4.2 +/- 2.2 vs 2.5 +/- 1.9 mg/dL; estimated glomerular filtration rate, 19.3 +/- 10.2 vs 45.9 +/- 30.1 mL/min/1.73 m(2)). ANCA-positive patients with IgA nephropathy had a higher percentage of crescentic glomeruli (54.3% +/- 18%) compared with ANCA-negative patients with crescentic IgA nephropathy (34.5% +/- 26%). ANCA-positive patients were treated using cyclophosphamide and corticosteroids. Kidney function improved in all these patients: serum creatinine level decreased from the peak of 4.2 +/- 2.2 to 1.7 +/- 0.7 mg/dL at the end of follow up (estimated glomerular filtration rate, 19.3 +/- 10.2 to 44.6 +/- 11.1 mL/min/1.73 m(2)). In contrast, no significant improvement was achieved in ANCA-negative patients. CONCLUSION: Patients with IgA nephropathy, crescents, and positive for ANCAs represent a clinical entity with a diverse more exaggerated clinical and histologic picture. However, disease in these patients responded well to aggressive immunosuppressive therapy. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

47. Dialysis systems/equipment Effect of Vitamin E Dialyzer Membrane on Anemia in Hemodialysis Patients.

Author

Kirmizis, D., Papagianni, A., Belechri, A. M., Alexopoulos, E., and Memmos, D.

Subjects
VITAMIN E, HEMODIALYZERS, HEMODIALYSIS patients, ERYTHROCYTES, ANEMIA
Abstract

Red blood cell (RBC) survival in patients on chronic maintenance hemodialysis (HD) has been reported to be shortened due to the oxidative damage of RBC membrane. The use of antioxidants might help in the control of anemia and reduce the erythropoietin (EPO) dose needed. The objective was to determine the effects of vitamin E-bonded dialyzer membrane (VEM) on anemia and EPO requirements in chronic HD patients. We prospectively studied 19 stable patients on HD (8 males, age 58.47, range 31–76 years) who were shifted from other dialyzer membranes to VEM for 6 months. At baseline they were given a mean dose of EPO of 90.6 ± 51 U kg–1 BW–1 week–1. Clinical data, dry body weight corrected pre-dialysis RBC, hemoglobin, reticulocytes, serum iron and ferritin, complete biochemistry, iPTH, and CRP were studied at 3 and 6 months, while therapy scheme was reevaluated monthly. A significant rise, compared to the baseline, was found in hemoglobin and in RBC at 3 months of treatment (12.44 ± 1.16 g/dL vs. 11.2 ± 1.2 g/dL, p = 0.002; and 4.01 ± 0.53 × 106/μL vs. 3.64 ± 0.5 × 106/μL, p < 0.05) and at the end of follow-up (12.17 ± 1.33 g/dL vs. 11.2 ± 1.2 g/dL, p < 0.05; and 4.03 ± 0.53 × 106/μL vs. 3.64 ± 0.5 × 106/μL, p < 0.05). No significant change in serum iron and ferritin, reticulocytes, EPO dose used, iPTH, Kt/V, or CRP was found at the end of follow-up compared to the baseline (68.8 ± 17 mg/dL vs. 67.9 ± 18 mg/dL, p = NS; 421 ± 296 mg/dL vs. 478 ± 359 mg/dL, p = NS; 3.76 ± 0.89 × 104/μL vs. 3.82 ± 0.78 × 104/μL, p = NS; 90.2 ± 53 U kg–1 BW–1 week–1 vs. 90.6 ± 51 U kg–1 BW–1 week–1, p = NS; 157 ± 43 pg/dL vs. 148 ± 56 pg/dL, p = NS; 1.21 ± 0.22 vs. 1.2 ± 0.17, p = NS; 7.15 ± 5.42 mg/L vs. 15.38 ± 29.8 mg/L, p = NS, respectively). Despite the small number of patients and the short time interval of treatment, an antioxidant effect of VEM apparently achieved early a better control of anemia in HD patients. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

48. Obituary.

Author

Memmos, D.

Subjects
ALEXOPOULOS, Efstathios
Abstract

An obituary for nephrology professor Efstathios Alexopoulos is presented.

Published
2009
Full Text
View/download PDF

49. Unit dosing of darbepoetin alfa for the treatment of anemia in patients with end-stage renal disease being switched from recombinant human erythropoietin: results of a phase IIIb, 27-week, multicenter, open-label study in Greek patients.

Author

Bristoyiannis G, Germanos N, Grekas D, Hatzidimitriou C, Iatrou C, Memmos D, Moutafis S, Papachristoforou K, Papadoniou A, Pappas M, Sakellariou GA, Siamopoulos KC, Sombolos K, Stamatelou K, Stathakis CP, Stavgiannoudakis G, Stratigis S, Syrganis C, Tsakiris D, and Valis D

Abstract

Background:Darbepoetin alfa is an erythropoietis-stimulating glycoprotein with a approximately 3-fold longer t1/2 and greater biological activity compared with recombinant human erythropoietin (rHuEPO).Objective:The objective of this study was to evaluate the efficacy andtolerability of long-term (24-week) darbepoetin alfa treatment in maintaining hemoglobin (Hb) concentrations in the target range of 10 to 13 g/dL in patients undergoing dialysis; the patients were switched from rHuEPO to a less-frequent dosing regimen of darbepoetin alfa without an increase in dose.Methods:In this Phase IIlb, open-label, multicenter study, patients withend-stage renal disease (ESRD) undergoing dialysis who were receiving rHuEPO BIW or TIW at baseline were switched to darbepoetin alfa QW; patients receiving rHuEPO QW were switched to darbepoetin alfa Q2W Administration of darbepoetin alfa was by the same route as previous rHuEPO administration (IV or SC). Patients received darbepoetin alfa for 24 weeks, including a 20-week drug titration period followed by a 4-week, stable-dose evaluation period. The mode, dose, and frequency of administration of darbepoetin alfa were compared with those of baseline rHuEPO. Tolerability assessment was based on spontaneous reporting and laboratory tests (hematology, vital sign measurement, iron status, and biochemistry).Results:The study comprised 173 patients who were divided into 2 groups by route of administration (IV group, n = 146; SC group, n = 27). Mean (SE) adjusted increases in Hb concentration from baseline to the evaluation period for patients receiving darbepoetin alfa QW were 0.94 (0.32) g/dL and 0.38 (0.30) g/dL for the IV or SC routes, respectively (P = 0.004 and NS, respectively). For patients receiving darbepoetin alfa Q2W the mean (SE) adjusted increases in Hb concentration were 0.08 (0.53) g/dL and 0.48 (0.35) g/dL for the IV and SC routes, respectively (both, P = NS). No significant differences in IV/SC dose ratio were observed between the 2 routes of administration. In addition, no increases in darbepoetin alfa dose were observed. The most commonly reported adverse events were hypertension (8 patients [5%]) and vascular access thrombosis (4 [2%]). The incidence of treatment-related adverse events was 6 (3%).Conclusions:Darbepoetin alfa effectively maintained Hb concentrations within the target range without an increase in dose, even at a reduced dosing frequency. Overall, darbepoetin alfa was well tolerated. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results